Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pamrevlumab versus placebo with systemic corticosteroids in non-ambulatory Duchenne muscular dystrophy
MOH_2020-12-21_009569Phase 3Active, not recruiting
- Sponsor
- FibroGen
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Pamrevlumab + systemic corticosteroids with Placebo + systemic corticosteroids (2 arms). Started Nov 2020; status: active, not recruiting.
02
Drugs
pamrevlumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2020-12-21_009569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-21_009569.